NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









KeViRx, Inc.

KeViRx, Inc.

Private
Charlottesville, VirginiaHealthcare & Life Scienceshttps://kevirx.com/

Last Round

Accelerator

Aug 28, 2024

Total Funding Raised

$3.05M

Company Overview

KeViRx, Inc. is a biotechnology company that develops small molecule drugs to treat microvascular leakage and inflammation for diseases such as acute lung injury.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

biotechnologydrug discoverysmall molecule therapeuticsacute lung injuryALIacute respiratory distress syndromeARDSbiotech startupendothelial barrier functionPTP4A3 phosphatase inhibitorhost-directed therapypreclinical developmentpulmonary microvascular leakagedrug developmentbiotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

KeViRx, Inc. Comparables

Compare KeViRx, Inc. with similar companies based on industry and business-model similarity.

KeViRx, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vasomune Therapeutics
88%
CMTx Biotech, Inc.
79%
Aqualung Therapeutics Corporation
78%

KeViRx, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorAug 28, 2024
GrantJun 11, 2024
GrantAug 29, 2022
AcceleratorFeb 18, 2022
GrantOct 5, 2021
Grant
Jun 15, 2020

Key People

Founding team and executive leadership

Elizabeth Sharlow

Chief Executive Officer and co-founder

Founding Team

KeViRx, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 11, 2024

    Secured $2M from the U.S. Department of Defense and Department of War.

  • Aug 29, 2022

    $75K grant from Virginia Innovation Partnership Corporation

KeViRx, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

KeViRx, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about KeViRx, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersCharlottesville, Virginia
Employee Range6
Year Founded2016
Last FundingAug 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.